Melatonin and Antidepressants (SSRIs): Can They Be Combined?

Melatonin and SSRI antidepressants (selective serotonin reuptake inhibitors) are two of the most commonly used substance groups affecting sleep and mood. The question of combining them arises naturally, since sleep disorders and depression often coexist — some patients with diagnosed depression reach for melatonin on their own, without telling their doctor, believing it's “just a natural supplement” rather than something requiring a pharmacological consultation.

Melatonin is metabolized in the liver mainly by the cytochrome P450 enzyme CYP1A2, which converts it into inactive metabolites before it's eliminated. Fluvoxamine is one of the strongest known CYP1A2 inhibitors among psychiatric drugs — it inhibits this enzyme far more strongly than other SSRIs such as citalopram, sertraline, or escitalopram, which have little to no meaningful effect on CYP1A2.

When fluvoxamine blocks this enzyme, orally taken melatonin isn't metabolized at its normal rate — its blood concentration rises and stays elevated longer than it would without the drug present. This is a classic example of a pharmacokinetic “metabolism inhibition” interaction, analogous to the one described in our article on grapefruit and statins, though a different enzyme (CYP3A4) and a different pair of substances are involved there.

This interaction's scale isn't marginal. A pharmacokinetic study found that fluvoxamine increases total exposure to melatonin (measured as area under the concentration curve, AUC) by up to 2.8-fold compared to melatonin alone. That means a standard melatonin dose — say, 1–3 mg — in someone taking fluvoxamine may act pharmacokinetically like a much higher dose, with correspondingly stronger and longer sedative effects.

Importantly, this effect is specific to fluvoxamine, not the whole SSRI class. Comparative studies have shown that citalopram, unlike fluvoxamine, doesn't raise melatonin levels at all. This distinction matters because patients, and sometimes imprecise online sources, speak generally of “melatonin interacting with SSRIs,” which is imprecise and can lead to two mistakes at once: unnecessary worry among people on other SSRIs, and underestimation of real risk among people on fluvoxamine.

Fluvoxamine is prescribed less often than sertraline or escitalopram for typical depression — it's used more frequently for obsessive-compulsive disorder (OCD) and certain anxiety disorders, which means general practitioners and pharmacists encounter this specific combination less often in everyday practice than, say, sertraline. This raises the risk that the interaction gets missed, especially if the patient reaches for over-the-counter melatonin without mentioning it as something worth reporting during a visit.

An added complicating factor is that fluvoxamine also inhibits another enzyme, CYP2C19, to a lesser extent involved in melatonin metabolism, which may further, though more weakly, contribute to the extended effect. In practice, this means that in someone taking fluvoxamine, melatonin's effect may be not only stronger but also more prolonged through the day than the typically expected 1–2 hours of evening sedation.

This myth is a variant of a broader cognitive bias about “natural” substances — also described in our article on ashwagandha and sedatives. The liver's metabolic machinery doesn't distinguish whether a substance comes from the body, from a plant, or from chemical synthesis — it only recognizes chemical structure and the corresponding enzymatic pathway.

This topic is a good example of why precision in pharmacology matters practically, not just academically. Generalizing that “melatonin and SSRIs don't mix” would be needlessly alarming for most patients, and generalizing that “it's safe, it's just a natural supplement” would miss a real, measured interaction in people on fluvoxamine. As is often the case in clinical pharmacology, the truth lies in the specifics — which drug, which enzyme, what scale of effect.